Navigation Links
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Date:6/25/2008

d cause actual results to differ materially from those projected, including: whether Vical or others will continue development of the RapidResponse(TM) DNA vaccine platform; whether the company will receive all, if any, of the NIH grant funding; whether the RapidResponse(TM) platform will reduce the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak and overcome the time, capacity and cost challenges of manufacturing conventional vaccines; whether RapidResponse(TM) platform will successfully be scaled up to allow the production of hundreds of millions of doses of DNA vaccines during the earliest stages of an outbreak; whether the RapidResponse(TM) platform will be applicable to a broad range of emerging diseases; whether the company's DNA vaccine candidates will be effective against emerging pathogens; whether the influenza vaccine or any other product candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market the influenza vaccine or any other product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; whether the company's issued patents will be challenged and whether such challenges will have an adverse effect on the scope of the patents; whether the company will enforce its issued patents or will be successful in any enforcement efforts; whether the company will be issued additional patents on the RapidResponse(TM) process or applications; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring


'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
(Date:9/30/2014)... , Sept. 30, 2014  HealthLoop® released an ... with HealthKit in iOS 8 and allows people to ... The app harnesses native iOS technologies to enhance the ... a robust connection with their doctors between visits. ... and the data they collect is exciting," says HealthLoop ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 ... oncology tissue diagnostics market, Frost & Sullivan recognizes ... the Roche Group, with the 2014 North American ... Adherence to strict quality practices along with a ... made Ventana a global leader in tissue-based cancer ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... and Drug Administration today issued new guidance that advises ... to administer influenza vaccinations. Based on this advice, The ... use of such clinical devices at all pharmacies and ... family of pharmacies and The Little Clinic locations will ...
... 21, 2011 Boca Pharmacal, Inc., today announced that it ... Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and ... and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, ... in the treatment of peptic ulcers. "We,re up ...
Cached Medicine Technology:Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets 2
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 Elevate ... helping people perform better in and out of the gym ... memory has caught the attention of Shane Michaels, prompting an ... grind, fatigue is the reason most people simply just don’t ... that means staying focused at work, getting the motivation to ...
(Date:9/30/2014)... 2014 VisitandCare.com reports that ... gone up more than 79 percent in 2014, marking ... also reported total revenue tripled for its entirety of ... professional strategy has allowed them to partner with ... patient comfort and privacy — with state-of-the-art surgical atmospheres ...
(Date:9/30/2014)... 2014 Hospice & Palliative Care ... Celebration” gala, honoring three outstanding individuals for their ... to provide extraordinary and dignified comfort, care and ... or life-limiting illness. , The event was held ... and recognized William (Bill) J. McGuinness, Director of ...
(Date:9/30/2014)... September 30, 2014 Regenerative Medicine Solutions ... new clinics in Nashville, Tennessee. RMS welcomes the launch ... and the expansion of a new treatment center for ... the Sleep Apnea Institute to Nashville, the hope is ... sleep apnea: both diagnosed and undiagnosed. With Nashville being ...
(Date:9/30/2014)... Dr. Karl R.O.S. Johnson, DC, has ... of care that is dramatically improving the health and ... Neurology & Nutrition—applies a proprietary, multi-dimensional approach that goes ... sources of inflammation, neurology of the joint and neurology ... the brain to the spine, to the legs, knees ...
Breaking Medicine News(10 mins):Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... Rap music especially prone to these types of lyrics, ... About one-third of hit songs -- including three-quarters of ... to drug, alcohol or tobacco use, a new study ... (41.6 percent) had a substance use reference of any ...
... Billion of Additional Medicare Cuts to Home Oxygen ... to Take Affect in Less than,One Year, ... Care (CQRC) -- a coalition of the nation,s ... expressed sincere,disappointment today in response to cuts to ...
... Lance Armstrong Foundation joins first global effort focusing on ... dangers of parental smoking in homes ... the first global initiative of,its kind, the Lance Armstrong ... global consortium of cancer-fighting,organizations, will lead a year-long communication, ...
... Inc.,(Nasdaq: ATSI ), manufacturer and marketer of ... revenue results,for the fourth quarter and full year ... ), The Company currently expects revenue for ... which would represent an increase of,approximately 32% over ...
... 2009, if enacted, would spell disaster for the nations ... to the HIV/AIDS epidemic in the United States. ... for research at the National Institutes of Health (NIH), ... and Prevention (CDC), and vital health care safety net ...
... Pairs of Shoes Symbolizing Deaths Caused by Tobacco,Use in ... the,statewide youth advocacy group H.O.T. (Helping Overcome Tobacco) will,gather ... Capitol Rotunda to,highlight the problem of tobacco use in ... on the steps of the Capitol, representing the,number of ...
Cached Medicine News:Health News:1 in 3 Hit Songs Mentions Substance Abuse, Smoking 2Health News:Home Oxygen Care Leaders Say President's Budget Will Lead to Significant Patient Service Disruptions, Call for Thoughtful Reforms as Opposed to Repeated Cuts 2Health News:Home Oxygen Care Leaders Say President's Budget Will Lead to Significant Patient Service Disruptions, Call for Thoughtful Reforms as Opposed to Repeated Cuts 3Health News:World Cancer Campaign Builds Momentum Globally with International Initiative to Protect Children From Secondhand Smoke 2Health News:World Cancer Campaign Builds Momentum Globally with International Initiative to Protect Children From Secondhand Smoke 3Health News:ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32% 2Health News:2009 Bush budget a disaster for HIV/AIDS 2
... Streptavidin magnetic beads are designed ... biotinylated molecules such as DNA, ... cell lysates or hybridization reactions. ... dispersed, it can also be ...
... Streptavidin magnetic beads are ... covalently coupled to a ... substrates can be useful ... experiments including mRNA isolation ...
... For the detection P.falciparum ... and pan specific pLDH, for differentiation ... other malarial species viz P.vivax ... P. malariae and for the ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
Medicine Products: